MX2017008520A - Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). - Google Patents

Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2017008520A
MX2017008520A MX2017008520A MX2017008520A MX2017008520A MX 2017008520 A MX2017008520 A MX 2017008520A MX 2017008520 A MX2017008520 A MX 2017008520A MX 2017008520 A MX2017008520 A MX 2017008520A MX 2017008520 A MX2017008520 A MX 2017008520A
Authority
MX
Mexico
Prior art keywords
hiv
treatment
pyrimidine compounds
fused pyrimidine
compounds
Prior art date
Application number
MX2017008520A
Other languages
English (en)
Inventor
L Mackman Richard
Jansa Petr
Kvasnica Miroslav
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2017008520A publication Critical patent/MX2017008520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se describen compuestos de la Fórmula (I) y tautómeros y sales farmacéuticas de los mismos, composiciones y formulaciones que contienen estos compuestos, y métodos de uso y elaboración de estos compuestos.
MX2017008520A 2014-12-24 2015-12-23 Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). MX2017008520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096820P 2014-12-24 2014-12-24
PCT/US2015/000308 WO2016105532A1 (en) 2014-12-24 2015-12-23 Fused pyrimidine compounds for the treatment of hiv

Publications (1)

Publication Number Publication Date
MX2017008520A true MX2017008520A (es) 2018-03-01

Family

ID=55135505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008520A MX2017008520A (es) 2014-12-24 2015-12-23 Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).

Country Status (16)

Country Link
US (1) US9701677B2 (es)
EP (1) EP3237414B1 (es)
JP (1) JP6385584B2 (es)
KR (1) KR101985122B1 (es)
CN (1) CN107207498B (es)
AU (1) AU2015371255B2 (es)
BR (1) BR112017013491A2 (es)
CA (1) CA2972014C (es)
EA (1) EA032430B1 (es)
ES (1) ES2735087T3 (es)
HK (1) HK1244270B (es)
IL (1) IL253060A0 (es)
MX (1) MX2017008520A (es)
NZ (1) NZ733135A (es)
SG (1) SG11201705192PA (es)
WO (1) WO2016105532A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TW202138365A (zh) 2016-08-19 2021-10-16 美商基利科學股份有限公司 治療性化合物
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN111836805B (zh) * 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
TWI745652B (zh) 2018-02-16 2021-11-11 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
CN111094289B (zh) 2018-07-03 2022-11-22 江苏恒瑞医药股份有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
IL286328B1 (en) 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
EP4643882A3 (en) 2019-11-26 2026-01-14 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022093552A2 (en) * 2020-10-16 2022-05-05 Saint Louis Univeristy Rev-erb agonists
JP7659628B2 (ja) 2020-11-11 2025-04-09 ギリアード サイエンシーズ， インコーポレイテッド ｇｐ１２０ ＣＤ４結合部位指向性抗体による治療に感受性のＨＩＶ患者を特定する方法
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
PT4440702T (pt) 2021-12-03 2025-08-13 Gilead Sciences Inc Compostos terapêuticos para a infecção pelo vírus do hiv
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
EP4719608A1 (en) 2023-05-31 2026-04-08 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
AU2024281548A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
KR20260046169A (ko) 2023-07-28 2026-04-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
AU2024360779A1 (en) 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN122055369A (zh) 2023-10-11 2026-05-15 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
EP1218358B1 (en) * 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
EP1235815A1 (en) 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
CA2422488A1 (en) 2000-09-20 2002-03-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-amino-quinazolines
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
WO2004108711A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8153640B2 (en) * 2004-10-29 2012-04-10 Tibotec Pharmaceuticals Ltd. HIV inhibiting bicyclic pyrimdine derivatives
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
WO2006099301A2 (en) 2005-03-10 2006-09-21 The Regents Of The University Of California Apoptosis inhibitors
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008050808A1 (fr) 2006-10-24 2008-05-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
RU2009128688A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные циклоалкиламином производные изохинолина и изохинолинона
RU2457203C2 (ru) 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
US20090004185A1 (en) 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
WO2008122614A1 (en) 2007-04-06 2008-10-16 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CN102015660A (zh) 2008-04-23 2011-04-13 协和发酵麒麟株式会社 2-氨基喹唑啉衍生物
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2381943A1 (en) 2008-12-29 2011-11-02 Fovea Pharmaceuticals Substituted quinazoline compounds
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
PH12013500015A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
WO2012044090A2 (ko) 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2769723A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物

Also Published As

Publication number Publication date
BR112017013491A2 (pt) 2018-01-09
CA2972014C (en) 2019-09-24
KR101985122B1 (ko) 2019-05-31
KR20170131352A (ko) 2017-11-29
EP3237414B1 (en) 2019-05-08
EA032430B1 (ru) 2019-05-31
WO2016105532A1 (en) 2016-06-30
US20160251347A1 (en) 2016-09-01
NZ733135A (en) 2018-06-29
JP6385584B2 (ja) 2018-09-05
JP2018500357A (ja) 2018-01-11
CN107207498A (zh) 2017-09-26
HK1244276A1 (zh) 2018-08-03
IL253060A0 (en) 2017-08-31
AU2015371255A1 (en) 2017-07-13
CA2972014A1 (en) 2016-06-30
CN107207498B (zh) 2020-03-24
HK1244270B (en) 2020-05-22
AU2015371255B2 (en) 2018-09-27
US9701677B2 (en) 2017-07-11
ES2735087T3 (es) 2019-12-16
SG11201705192PA (en) 2017-07-28
EP3237414A1 (en) 2017-11-01
EA201791305A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12017501191A1 (en) Quinazoline derivatives used to treat hiv
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12015502615B1 (en) Chemical compounds
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
TW201613864A (en) Novel compounds
MY192216A (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
MX2017014035A (es) Formas solidas novedosas.
TN2015000313A1 (en) Chemical compounds
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.